27
Participants
Start Date
February 15, 2022
Primary Completion Date
May 16, 2023
Study Completion Date
May 16, 2023
Treatment A
Administration of a 3 mg dose of prolonged-release tacrolimus (Advagraf®)
Treatment B
Administration of a 2 mg dose of LCP-tacro (Envarsus®)
Treament C
Administration of a single 120 mg dose of immediate-release verapamil (Isoptine®) and a 3 mg dose of prolonged-release tacrolimus (Advagraf®)
Treatment D
Administration of a single 120 mg dose of immediate release verapamil (Isoptine®) and a 2 mg dose of LCP-tacro (Envarsus®)
Pharmacocinetik
Nine sampling points of 7 ml each will be taken on the first day at the CIC UIC and the last sampling point will be carried out at 24 hours from the administration the following morning.
Genetic
A genetic analysis to determine your characteristics for enzymes in your metabolism as well as transport proteins will be carried out. An additional 7 ml blood tube will be drawn for this purpose during the first period.
Selection visit:
"During this visit, it will be asked to sign the following consent and it will be carried out:~* a clinical examination (questioning and physical examination with measurement of height and weight);~* a blood test (18 mL);~* a blood pregnancy test if you are a woman;~* a cardiac assessment (electrocardiogram).~These results should be normal."
CHU de Rennes, Rennes
Rennes University Hospital
OTHER